Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) approved olaparib (Lynparza) as a maintenance treatment for patients with BRCA
-mutant ovarian cancer after undergoing first-line chemotherapy.
The approval was based on findings from the randomized, double-blinded, phase III SOLO-1 study, in which maintenance olaparib significantly improved progression-free survival (PFS) compared with placebo in this patient population following frontline platinum-based chemotherapy.
Olaparib is the sole PARP inhibitor that is approved for use in Japan.
... to read the full story